Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.32
+0.02000.87%
Post-market: 2.340.0161+0.69%19:30 EDT
Volume:658.02K
Turnover:1.52M
Market Cap:278.40M
PE:-2.20
High:2.36
Open:2.34
Low:2.27
Close:2.30
52wk High:3.23
52wk Low:0.9500
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.42
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.81
PE(LYR):-2.02

Loading ...

H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)

TIPRANKS
·
Jun 24

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jun 22

Fate Therapeutics Shareholders Back Directors and Governance Plans

TIPRANKS
·
Jun 16

Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan

Reuters
·
Jun 16

BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of Directors

Reuters
·
Jun 15

Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board

Reuters
·
Jun 15

Press Release: Fate Therapeutics Appoints Laura Hamill to Board of Directors

Dow Jones
·
Jun 15

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

TIPRANKS
·
Jun 09

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 08

Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)

TIPRANKS
·
Jun 06

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline

TIPRANKS
·
Jun 05

Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability

TIPRANKS
·
Jun 05

Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen

Reuters
·
Jun 04

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

GlobeNewswire
·
Jun 04

Fate Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Jun 04

Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan

Reuters
·
Jun 03

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 03

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo

Reuters
·
Jun 01